dc.contributorUniversidade Federal de Minas Gerais (UFMG)
dc.contributorFIOCRUZ
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:21:06Z
dc.date.accessioned2022-10-05T17:53:07Z
dc.date.available2014-05-27T11:21:06Z
dc.date.available2022-10-05T17:53:07Z
dc.date.created2014-05-27T11:21:06Z
dc.date.issued2004-07-01
dc.identifierCanadian Journal of Microbiology, v. 50, n. 7, p. 514-520, 2004.
dc.identifier0008-4166
dc.identifierhttp://hdl.handle.net/11449/67775
dc.identifier10.1139/w04-025
dc.identifierWOS:000224057700009
dc.identifier2-s2.0-6344275553
dc.identifier6543563161403421
dc.identifier0000-0002-2416-2173
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3917391
dc.description.abstractPCR was used to amplify a targeted region of the ribosomal DNA of 76 Candida spp. isolates from immunocompromised and seriously diseased patients. Thirty-seven strains isolated from different anatomical sites of 11 patients infected with HIV (Vitória, ES, Brazil), 26 isolates from patients under treatment at Odilon Behrens Hospital and 13 isolates from skin and urine samples from São Marcos Clinical Analysis Laboratory (Belo Horizonte, Brazil) were scored. Fragments of rDNA were amplified using primer pairs ITS1-ITS4, for the amplification of ITS1 and ITS2 regions, including the gene for the 5.8s subunit. Amplification resulted in fragments ranging in size from 350 to 950 bp. Amplicons were digested with eight restriction enzymes. A pattern of species-specificity among the different medically important Candida species could be identified following restriction digestion of the PCR products. Candida albicans was the species most frequently observed, except for the group of newborns under treatment at the Odilon Behrens Hospital and for the isolates from the clinical analysis laboratory. C. parapsilosis was the species most frequently observed in these two groups.
dc.languageeng
dc.relationCanadian Journal of Microbiology
dc.relation1.243
dc.relation0,579
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectCandida spp.
dc.subjectCandidosis
dc.subjectPolymerase chain reaction
dc.subjectRestriction fragment length polymorphism
dc.subjectBiodiversity
dc.subjectBody fluids
dc.subjectDNA
dc.subjectEnzymes
dc.subjectHospitals
dc.subjectImmunology
dc.subjectPatient treatment
dc.subjectViruses
dc.subjectCandida species
dc.subjectClinical analysis laboratory
dc.subjectFragments
dc.subjectUrine samples
dc.subjectMicrobiology
dc.subjectrestriction endonuclease
dc.subjectribosome DNA
dc.subjecthuman immunodeficiency virus
dc.subjectidentification method
dc.subjectpolymerase chain reaction
dc.subjectamplicon
dc.subjectCandida
dc.subjectCandida albicans
dc.subjectcandidiasis
dc.subjectcontrolled study
dc.subjectdisease severity
dc.subjectfungus identification
dc.subjectgene amplification
dc.subjecthuman
dc.subjectimmune deficiency
dc.subjectnonhuman
dc.subjectopportunistic infection
dc.subjectpriority journal
dc.subjectrestriction fragment length polymorphism
dc.subjectskin
dc.subjectspecies difference
dc.subjecturine
dc.subjectCandidiasis
dc.subjectCluster Analysis
dc.subjectDNA Fingerprinting
dc.subjectDNA Restriction Enzymes
dc.subjectDNA, Fungal
dc.subjectDNA, Ribosomal
dc.subjectDNA, Ribosomal Spacer
dc.subjectEpidemiology, Molecular
dc.subjectGenes, rRNA
dc.subjectHumans
dc.subjectImmunocompromised Host
dc.subjectMycological Typing Techniques
dc.subjectPhylogeny
dc.subjectPolymerase Chain Reaction
dc.subjectPolymorphism, Restriction Fragment Length
dc.subjectRNA, Ribosomal, 5.8S
dc.subjectCandida parapsilosis
dc.subjectFungi
dc.subjectHuman immunodeficiency virus
dc.titlerDNA-RFLP identification of Candida species in immunocompromised and seriously diseased patients
dc.typeArtigo


Este ítem pertenece a la siguiente institución